Aspectos farmacocinéticos e analgésicos da fenilbutazona em equinos
Carregando...
Arquivos
Data
2011-08-02
Autores
Bopp, Simone [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
Os equinos apresentam predisposição elevada às lesões do sistema locomotor desenvolvendo, em consequência disso, respostas inflamatória e álgica. O anti-inflamatório não esteroidal fenilbutazona é um dos fármacos mais utilizados no tratamento da inflamação e da dor músculo-esquelética nos equinos. Objetivou-se com este estudo avaliar os efeitos clínicos da administração em dose única de fenilbutazona nas doses de 2,2, 4,4 ou 16,6 mg/kg por via intravenosa em equinos submetidos à claudicação experimental reversível induzida por dois parafusos fixados à ferradura, ajustados para exercerem pressão solear e, consequentemente, causar desconforto e claudicação controlada. Por meio deste modelo, estudou-se a concentração plasmática da fenilbutazona e da oxifembutazona e a resposta clínica de seis equinos adultos, saudáveis submetidos a três doses de fenilbutazona, em um intervalo de sete dias. Os parafusos foram apertados e ajustados para produzirem compressão solear capaz de induzir claudicação de grau 3 ou 4, segundo escala da AAEP, e foram mantidos por um período de 24h. Avaliou-se grau de claudicação, frequência cardíaca, frequência respiratória, pressão arterial sistólica, sons intestinais, concentração plasmática da fenilbutazona e oxifembutazona, parâmetros hematológicos e bioquímicos. As três doses demonstraram eficácia clínica, sem produção de efeitos adversos. A concentração plasmática da fenilbutazona e da oxifembutazona foi diretamente proporcional à dose aplicada, entretanto o aumento da dose não aumentou a eficácia, haja vista que não houve diferença entre os tratamentos com fenilbutazona na redução do grau de claudicação
Horses present high predisposition to lesions in the locomotor system and consequent development of inflammatory and pain responses. Nonsteroidal anti-inflammatory phenylbutazone is one of the most used drugs in the treatment of inflammation and musculoskeletal pain in horses. The aim of this study was to evaluate the clinical effects of single intravenous administration of phenylbutazone in doses of 2.2, 4.4 or 16.6 mg/kg in horses submitted to experimental reversible lameness induced by two screws attached to horseshoe and adjusted to exert solar pressure and cause discomfort and controlled lameness. By this model, we studied plasma concentration of phenylbutazone and oxyphenbutazone and clinical response of six adult healthy horses submitted to three doses of phenylbutazone in an interval of seven days. Screws were tightened and adjusted to produce compression of the sole and induce lameness of third or fourth degree, according to the AAEP scale, staying in place for 24 hours. We have assessed lameness degree, heart rate, respiratory rate, systolic blood pressure, bowel sounds, plasma concentration of phenylbutazone and oxyphenbutazone, and hematological and biochemical parameters. All three doses of phenylbutazone demonstrated clinical efficacy without producing adverse effects. Plasma concentration of phenylbutazone and oxyphenbutazone was directly proportional to the applied dose, however the increase of dose did not increase its efficiency, since there was no difference between treatments with phenylbutazone in the reduction of the degree of lameness.
Horses present high predisposition to lesions in the locomotor system and consequent development of inflammatory and pain responses. Nonsteroidal anti-inflammatory phenylbutazone is one of the most used drugs in the treatment of inflammation and musculoskeletal pain in horses. The aim of this study was to evaluate the clinical effects of single intravenous administration of phenylbutazone in doses of 2.2, 4.4 or 16.6 mg/kg in horses submitted to experimental reversible lameness induced by two screws attached to horseshoe and adjusted to exert solar pressure and cause discomfort and controlled lameness. By this model, we studied plasma concentration of phenylbutazone and oxyphenbutazone and clinical response of six adult healthy horses submitted to three doses of phenylbutazone in an interval of seven days. Screws were tightened and adjusted to produce compression of the sole and induce lameness of third or fourth degree, according to the AAEP scale, staying in place for 24 hours. We have assessed lameness degree, heart rate, respiratory rate, systolic blood pressure, bowel sounds, plasma concentration of phenylbutazone and oxyphenbutazone, and hematological and biochemical parameters. All three doses of phenylbutazone demonstrated clinical efficacy without producing adverse effects. Plasma concentration of phenylbutazone and oxyphenbutazone was directly proportional to the applied dose, however the increase of dose did not increase its efficiency, since there was no difference between treatments with phenylbutazone in the reduction of the degree of lameness.
Descrição
Palavras-chave
Claudicação em equino, Dor, Fenilbutazona, Oxifembutazona, Lameness, Pain, Phenylbutazone, Oxyphenbutazone
Como citar
BOPP, Simone. Aspectos farmacocinéticos e analgésicos da fenilbutazona em equinos. 2011. xvi, 63 f. Tese (doutorado) - Universidade Estadual Paulista, Faculdade de Ciências Agrárias e Veterinárias, 2011.